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Abstract
Mycobacterium microti is an animal- adapted member of the Mycobacterium tuberculosis complex (MTBC), which was originally isolated 
from voles, but has more recently also been isolated from other selected mammalian hosts, including occasionally from humans. Here, 
we have generated and analysed the complete genome sequences of five representative vole and clinical M. microti isolates using 
PacBio- and Illumina- based technologies, and have tested their virulence and vaccine potential in SCID (severe combined immune defi-
cient) mouse and/or guinea pig infection models. We show that the clinical isolates studied here cluster separately in the phylogenetic 
tree from vole isolates and other clades from publicly available M. microti genome sequences. These data also confirm that the vole and 
clinical M. microti isolates were all lacking the specific RD1mic region, which in other tubercle bacilli encodes the ESX-1 type VII secre-
tion system. Biochemical analysis further revealed marked phenotypic differences between isolates in type VII- mediated secretion of 
selected PE and PPE proteins, which in part were attributed to specific genetic polymorphisms. Infection experiments in the highly 
susceptible SCID mouse model showed that the clinical isolates were significantly more virulent than the tested vole isolates, but still 
much less virulent than the M. tuberculosis H37Rv control strain. The strong attenuation of the ATCC 35872 vole isolate in immunocom-
promised mice, even compared to the attenuated BCG (bacillus Calmette–Guérin) vaccine, and its historic use in human vaccine trials 
encouraged us to test this strain’s vaccine potential in a guinea pig model, where it demonstrated similar protective efficacy as a BCG 
control, making it a strong candidate for vaccination of immunocompromised individuals in whom BCG vaccination is contra- indicated. 
Overall, we provide new insights into the genomic and phenotypic variabilities and particularities of members of an understudied clade 
of the MTBC, which all share a recent common ancestor that is characterized by the deletion of the RD1mic region.
DATA SUMMARY
Illumina sequencing data have been deposited in the European 
Nucleotide Archive (ENA) database under the study PRJEB2091 
for Mycobacterium microti strains OV254 (ERR027294), ATCC 
35782 (ERR027295), 94-2272 (ERR027298) and Maus IV 
(ERR027297); and under the study PRJEB40482 for M. microti 
strain Maus III (ERR4618952).
Whole- genome sequences of M. microti strains have been depos-
ited in the ENA database under the study PRJEB40500 and the 
following assembly accession numbers: OV254, GCA_904810325; 
ATCC 35782, GCA_904810335; 94-2272, GCA_904810365; 
Maus III, GCA_904810345; Maus IV, GCA_904810355.
INTRODUCTION
Within the Mycobacterium tuberculosis complex (MTBC), 
Mycobacterium microti is one of the earliest described 
members and belongs to the animal- adapted lineage [1, 2]. As 
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in the 1930s by Dr Wells from diseased voles of the species 
Microtus agrestis, which showed tuberculosis- like lesions 
[3]. Since then, this subtype of the tubercle bacillus has been 
identified in field and bank voles, wood mice and shrews, 
suggesting that wild rodents represent the main reservoir 
of M. microti [3–5]. However, M. microti was also found 
to sporadically infect various other domesticated and wild 
mammals, including cats [6, 7], dogs [8], pigs [6], wild boars 
[9], llamas [10, 11], squirrel monkeys [12] and meerkats [13]. 
Nevertheless, many of these additional host species might 
represent spillover infections potentially linked to rodents, 
especially for cats [7], which might occur from environmental 
contamination via sputum and saliva, or direct contact 
through skin lesion, bite or feeding [14].
In the late 1990s and early 2000s, M. microti infections have also 
been reported as the cause of human tuberculosis (TB) cases, as 
M. microti was the only mycobacterium that was isolated from 
the lungs of human immunodeficiency virus (HIV)- positive 
[15, 16] and HIV- negative [17, 18] TB patients. However, 
human TB cases caused by M. microti infections remain sparse 
and no evidence of direct human- to- human transmission is 
available, although it has been suggested [17]. To our knowl-
edge, only a few dozen human TB cases caused by M. microti 
have been reported so far, mainly in European countries, such 
as The Netherlands [16, 17, 19, 20], the UK [21–24], Germany 
[15, 18, 25, 26], Switzerland (discussed by Cavanagh et. al [5]), 
France [27] and the Czech Republic [28], but also recently 
in South Africa, where among the spoligotypes of 215 tested 
human isolates, 4 corresponded to M. microti- specific patterns 
[29]. Yet, prevalence of M. microti infections among humans 
might be underestimated due to the extremely slow growth of 
this mycobacterium in diagnostic culture media (6–8 weeks vs 
2–4 weeks for M. tuberculosis), and due to the difficulty of distin-
guishing it from M. tuberculosis if no genotyping is performed 
during TB diagnosis in addition to traditional bacteriological 
tests [17].
Interestingly, M. microti lacks a functional ESX-1 type 
VII secretion system due to a conserved deletion of the 
M. microti- specific region of difference 1 (RD1mic) [7, 30–32], 
which partially overlaps with the RD1BCG region that is absent 
from the Mycobacterium bovis BCG (bacillus Calmette–
Guérin) strain [33, 34]. In the past, some of the M. microti 
strains were actually used as live attenuated vaccines against 
TB in humans in the UK and the former Czechoslovakia 
[35–37]. In these large- scale vaccination trials, involving 
more than 5000 adolescents in the UK and more than 500 000 
new- borns in the city of Prague between 1950 and 1969 [37], 
M. microti- immunized individuals were protected to a similar 
extent as individuals vaccinated with BCG [36, 37]. While 
the M. microti strain used in the UK was described as ‘the 
vole bacillus’ [36], the M. microti strain used in Prague was 
known as the ‘M.P.’ strain, referring to the abbreviated form 
of ‘Murinus Praha’. The M.P. strain originates from Dr Wells’ 
OV166 strain, isolated from Orkney voles [3], which was then 
adapted by Dr Sula to fully synthetic medium and used for 
preparation of the different vaccine lots for human vaccination 
[37, 38]. This strain was later also deposited in the American 
Type Culture Collection (ATCC) and was previously available 
under the reference number ATCC 35872 (Fig. S1, available 
with the online version of this article).
In the current study, we sought to investigate the genomic 
diversity and the virulence spectrum inside the clade of 
M. microti strains. To this end, we selected two M. microti 
vole isolates, namely the widely used laboratory strain OV254 
[39–43] and the previously used vaccine strain ATCC 35872 
[37], as well as three clinical M. microti isolates, and combined 
whole- genome sequencing approaches, biochemical analysis 
of protein secretion, virulence evaluation in murine models 
and preclinical vaccination experiments. We first generated 
the complete, whole- genome sequences of the five selected 
M. microti strains by using PacBio- and Illumina- based 
technologies. We then tested selected M. microti strains 
for their virulence potential in severe combined immune 
deficient (SCID) mice. Finally, we used the ATCC 35782 
M.P. vaccine strain for vaccination experiments in a guinea 
pig model, which also included animals vaccinated with an 
ESX-1- complemented version of ATCC 35782, named ATCC 
35872::ESX-1, as well as BCG- Danish- vaccinated and unvac-
cinated control animals. Taken together, we explore several 
key aspects of the clade of M. microti to provide new insights 
into genomic organization, virulence and protective potential 
of this highly interesting clade of the MTBC.
Impact Statement
Mycobacterium microti is a natural ESX-1- deleted 
member of the Mycobacterium tuberculosis complex, 
which was originally identified as a disease- causing 
agent in voles, but has since then also been isolated from 
other mammalian hosts including, in rare cases, humans. 
To gain new insights in this particular understudied clade, 
we have characterized here five representative M. microti 
strains of vole and human origin by using whole- genome 
comparisons, protein secretion analyses and virulence 
assays in immunocompromised mice. Consistent with 
the lack of a functional ESX-1 type VII secretion system, 
we observed that the human M. microti isolates were less 
virulent than M. tuberculosis in mice, but more virulent 
than the attenuated Mycobacterium bovis BCG (bacillus 
Calmette–Guérin) strain, while the vole M. microti isolates 
were even less virulent than BCG in this model. Given that 
selected M. microti strains have been used in the past as 
successful anti- tuberculosis vaccines, we further investi-
gated the vaccination potential of one such M. microti vole 
isolate in a guinea pig model and found that it induced 
similar protection as BCG. Combined with the additional 
attenuation over BCG, this strain might represent a 
possible alternative anti- tuberculosis vaccine for immu-
nocompromised individuals, for whom BCG vaccination is 
not recommended.
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METHODS
Bacterial strains
M. microti OV254, which was originally isolated from 
voles in the UK in the 1930s [3], was obtained from M. J. 
Colston, MRC- NIMR, Mill Hill, London, UK. M. microti 
94-2272 was isolated in 1988 from the perfusion fluid of a 
41- year- old dialysis patient [17] and was kindly provided 
by L. M. Parsons, Wadsworth Center Albany, Albany, NY, 
USA. M. microti ATCC 35782 was previously purchased from 
the ATCC [designation: TMC 1608 (M.P. Prague)] (Fig. S1). 
M. microti Maus III (also known as strain 6740/00 or B3) and 
M. microti Maus IV (also known as strain 1479/99 or B4) 
were obtained from the collection of the National Refer-
ence Center for Mycobacteria, Forschungszentrum Borstel, 
Germany [30]. Typically, M. microti strains were grown either 
on Middlebrook 7H9 liquid medium (Difco) containing 
10 % (v/v) acid- dextrose- catalase (ADC; Difco), 0.2 % (w/v) 
pyruvic acid and 0.05 % (v/v) Tween 80, or on Middlebrook 
7H11 solid medium (Difco) supplemented with 10 % (v/v) 
oleic acid- dextrose- catalase (OADC; Difco).
Whole-genome sequencing data generation
Genomic DNA of M. microti strains was isolated by bead- 
beating, boiling and ethanol precipitation, as described 
previously [44]. Genomic DNA was processed using the 
SMRTbell template library preparation kit and sequenced at 
the Biomics platform of the Institut Pasteur (Paris, France) 
using the PacBio SMRT long- read sequencing technology 
(Chemistry v2.1; Sequel ICS v5.0.1; SMRT Link v5.0.1). In 
parallel, genomic DNA was also sequenced using the Illu-
mina paired- end short- read sequencing technology. Strains 
OV254, ATCC 35782, 94-2272 and Maus IV were sequenced 
at the Wellcome Trust Sanger Institute (Hinxton, UK) using 
a Genome Analyzer IIx device, while strain Maus III was 
sequenced at the Biomics platform of the Institut Pasteur 
(Paris, France) using a HiSeq 2500 device. Sequencing read 
datasets of additional M. microti strains for phylogenomic 
analyses were downloaded from the Sequence Read Archive 
(SRA) database: strain ATCC 19422 (also known as strain 
‘12’; run SRR3647357) [45]; strains isolated from wild 
boars in Italy G25821 to G25828 (runs from ERR2659163 
to ERR2659171) [46]; and llama- type strains 416/01 and 
8753/00 (runs ERR553376, ERR553377 and from ERR551111 
to ERR551113) [47].
Whole-genome assembly
Raw PacBio subreads were assembled using Canu v1.7 [48] 
(parameters: genomeSize=4.4m; -pacbio- raw). Generated 
supercontigs were then organized as compared to the genome 
of M. bovis BCG Pasteur 1173P2 (AM408590) [49] using 
MeDuSa v1.6 [50] (default parameters). Illumina read pairs 
were first trimmed using Trimmomatic v0.36 [51] (parameters: 
LEADING 20; TRAILING 20; SLIDINGWINDOW window-
Size 5, requiredQuality 20; MINLEN 50; AVGQUAL 20). 
Complete read pairs were then assembled using SPAdes v3.10.1 
[52] (parameters: --careful; -k 21,33,55; --phred- offset 33) and 
providing either raw PacBio subreads (parameter: --pacbio) 
or the scaffolds of PacBio supercontigs (parameter: --trusted- 
contigs). Illumina contigs thus generated were then compared 
to the PacBio scaffolds using blastn from blast+ v2.5.0+ [53] 
(parameters: -perc_identity 95; -dust no; -soft_masking no) to 
correct erroneous arrangements and to fill undefined gaps.
Gene annotation
Whole- genome assemblies of M. microti strains were anno-
tated using Prokka v1.13.4 [54] (parameters: --addgenes; 
--kingdom Bacteria; --gcode 11; --rfam; --rnammer). 
Genome annotation was performed against the default 
bacterial core databases, as well as against a custom Genus 
database (parameter: --usegenus) composed of annotated 
genes from M. tuberculosis H37Rv (AL123456), M. bovis 
AF2122/97 (LT708304) and M. bovis BCG Pasteur 1173P2 
(LT708304) [49, 55, 56]. Prediction and synteny analysis of 
orthologous genes was performed according to the Synima 
pipeline r20122018 [57]. Briefly, nucleotide sequences of all 
annotated protein- encoding genes were first compared using 
blastn from blast+ v2.2.26 [53]. Groups of orthologous 
genes were then determined from nucleotide alignments 
using OrthoMCL v1.4 [58], and chains of syntenic genes 
were retrieved using DAGchainer r02062008 [59]. Hierar-
chical clustering of orthologous genes was performed using 
the Ward’s D2 minimum variance method on asymmetric 
binary (Jaccard) distances.
Variant calling
Illumina read pairs were mapped against a given reference 
genome using bwa- mem v0.7.15 [60] (default parameters). 
Mapped reads were first locally realigned around indels using 
Picard Tools v2.8.1 (http:// broadinstitute. github. io/ picard/) 
and GATK RealignerTargetCreator and IndelRealigner tools 
v.3.7.0 [61] (default parameters). Read alignments with a 
mapping quality lower than one and flagged as secondary 
were then discarded using SAMtools view v1.3.1 [62] (param-
eters: -q 1; -F 256). Duplicated read pairs were also removed 
from the alignment map using an in- house Python script to 
prevent the presence of potential amplification contaminants. 
Two read pairs were considered as a duplicate if they mapped 
at the same positions, had an identical sequence and stemmed 
from the same DNA strand. In the case of duplicates, the pair 
with the highest base- quality mean was kept. The resulting 
alignment map was finally converted into pileup format using 
SAMtools mpileup v1.3.1 [62] (parameters: -B; -Q 0; -s). 
SNPs and indels were called using VarScan pileup2snp and 
pileup2indel v2.4.2 [63], respectively. To detect and correct 
sequencing errors within PacBio whole- genome assemblies, 
variants were called using a minimum read depth of 5 and a 
minimum variant frequency of 51 %. To identify genetic vari-
ations between two different strains, the called variants were 
filtered according to the VarScan detection criteria with the 
following adjustments to increase stringency: (i) a minimum 
read depth of 5; (ii) a minimum variant frequency of 80 %; 
(iii) a minimum mean base quality of 20; and (iv) a minimum 
variant support on each strand of 25 %. Effects of called SNPs 
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and indels on annotated genes were predicted using SnpEff 
ann v4.3i [64] (parameters: -no- upstream; -no- downstream). 
Variant intersections were determined using the R package 
UpSetR v1.3.3 [65]. Functional annotation and categorization 
of genes affected by variants was performed using RAST [66]. 
Density of mapped reads and filtered variants was calculated 
in 5- kb non- overlapping windows and plotted using Circos 
v0.69-6 [67].
Phylogenetic reconstruction
All variants detected for each M. microti strain against 
M. tuberculosis H37Rv were first filtered according to 
the reference annotation (AL123456.3) to remove those 
located within repetitive sequences, namely genes encoding 
proteins of the Pro- Glu (PE), Pro- Pro- Glu (PPE) and PE_
PGRS (Polymorphic GC- rich Sequence) families, mobile 
elements and repeat regions. Sequencing read depth at 
positions of the remaining variants was then parsed among 
all alignment maps to exclude variants for which the read 
coverage was lower than the minimum threshold fixed for 
variant calling (<5 mapped reads) in at least one strain. 
Remaining variants were finally used to produce a phylip 
alignment that contained only variable sites (SNPs). This 
resulting alignment, excluding ambiguous variants and 
indels, accounted for 74.7 % of the initial polymorphic sites. 
Maximum- likelihood phylogenetic reconstruction was 
inferred using RAxML v8.2.12 [68] with the GTR substitu-
tion model, GAMMA distribution of rate heterogeneity, 
Lewis’ correction of ascertainment bias and 1000 rapid 
bootstrap replicates (parameters: -m ASC_GAMMA; --asc- 
corr=lewis; -f a). Bipartition support of the best- scoring 
tree rooted using M. tuberculosis H37Rv was computed 
according to the transfer bootstrap expectation (TBE) from 
booster v0.1.2 [69]. The resulting maximum- likelihood 
phylogenetic tree that is shown was drawn and annotated 
using the R package ggtree v1.14.6 [70].
Secretion analysis and immunoblots
Secretion analysis was performed as described elsewhere 
[71, 72]. Briefly, strains ATCC 35782, 94-2272, Maus 
III, OV254 and OV254- C (OV254 transduced with the 
pMV::mt2419-22 vector that encodes the ppe38-71 genetic 
locus [73, 74]) were pre- cultured in general culture medium 
until an OD600 of approximately 1.0. At this point, cultures 
were washed three times in secretion medium, consisting 
of 7H9 medium without ADC, supplemented with 0.2 % 
(w/v) dextrose, 0.2 % (w/v) pyruvic acid and 0.025 % (v/v) 
Tween 80. Washed cells were inoculated at an OD600 of 0.5 
in secretion medium and were incubated 48 h at 37 °C. 
These cultures were harvested by centrifugation and the 
supernatant was filtered using a 0.22-µm filter (Millipore) 
and precipitated with trichloroacetic acid, before being 
resuspended and boiled 10 min at 95 °C in solubilization/
denaturation buffer. Cells were washed with PBS (1x) and 
resuspended in solubilization/denaturation buffer before 
being heat- inactivated for 3 h at 80 °C, followed by sonica-
tion to disrupt cells and boiling for 10 min at 95 °C. Protein 
samples were loaded on SDS- PAGE gels with an equivalent 
of 0.225 OD units for whole cell lysates and 0.6 OD units for 
culture filtrates. Western blots were stained with anti- PGRS 
antibody 7C4.1F7 (a kind gift of the antibody- producing 
clone was from M.J. Brennan, Aeras, Rockville, MD, USA; 
and of purified antibody from W. Bitter, Amsterdam UMC, 
Amsterdam, The Netherlands) [75]; anti- SigA (a kind gift 
from I. Rosenkrands, Statens Serum Institut, Copenhagen, 
Denmark); rabbit polyclonal anti- EsxN (rMtb9.9A) [76]; 
and rabbit polyclonal anti- PPE41 (a kind gift from W. Bitter, 
Amsterdam UMC, Amsterdam, The Netherlands) [77].
Virulence assay in SCID mice
For sample preparation, 50 ml cultures of the individual 
mycobacterial strains were grown in parallel in Middle-
brook 7H9 medium supplemented with 10 % (v/v) ADC, 
2 % (w/v) pyruvic acid and 0.05 % (v/v) Tween 80. Bacteria 
were harvested, washed and resuspended in 50 mM sodium 
phosphate buffer (pH 7.0). Bacterial suspensions, obtained 
by brief sonication with disinfected, sterile equipment were 
then aliquoted and frozen at −80 °C. A single defrosted 
aliquot was used to quantify the c.f.u. of stock solutions. A 
typical concentration of stock solutions was 109 c.f.u. ml−1. For 
virulence studies, 13 6- week- old female SCID mice (Charles 
River) per group were infected intravenously via the lateral 
tail vein with 1×106 c.f.u. in 200 µl of PBS (1x). After 1 day 
of infection, the delivered dose was determined from spleens 
from three representative control mice per group. Organs 
were homogenized using an MM300 (Qiagen) apparatus and 
2.5- mm diameter glass beads. Serial fivefold dilutions in PBS 
(1×) were plated on Middlebrook 7H11 OADC agar and c.f.u. 
were counted after 3–6 weeks of growth at 37 °C, depending 
on the strain. The weight of the 10 remaining mice per group 
was monitored over several weeks and mice were killed when 
reaching the humane endpoint, defined as a loss of >20 % of 
bodyweight in accordance with ethics committee guidelines. 
Sample size choice was determined by taking into account the 
rule of 3Rs (replacement, reduction, refinement) and statis-
tical requirements. Statistical significance in survival between 
groups of infected animals was assessed with the log- rank 
(Mantel–Haenszel) test using the R package survival v3.2-7 
[78]. For the pilot virulence assay, five SCID mice (Charles 
River) per group were infected intravenously and the deliv-
ered dose was determined from the spleen from one mouse 
per group on the day of infection.
Assessment of protective efficacy induced in 
guinea pigs
A low- dose aerosol guinea pig infection model was used as 
previously described [79, 80]. Dunkin Hartley guinea pigs 
free from pathogen- specific infection (weight 250–350 g) 
were randomly assigned to vaccine groups and identified 
using subcutaneously implanted microchips (Plexx) to 
enable blinding of the analyses wherever possible. Statistical 
power calculations (Minitab, version 16) were performed 
to determine group sizes using previous data (SD, approxi-
mately 0.5) to reliably detect a difference of 1.0 log10 in the 
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group median number of c.f.u. ml−1. Guinea pigs (eight per 
group) were vaccinated once subcutaneously on the nape 
with 5×104 c.f.u. in 250 µl of PBS (1x) M. microti strain 
ATCC 35782, ATCC 35782::ESX-1 or BCG Danish, or 
inoculated with saline as a control. At 12 weeks after immu-
nization, animals were challenged by the aerosol route with 
M. tuberculosis H37Rv NCTC 7416 (retained dose 10–20 
c.f.u./lungs). Protection was determined by measuring the 
bacterial load 4 weeks after challenge, when guinea pigs 
were killed by an overdose with sodium pentobarbital 
given by the intraperitoneal route. At necropsy, lungs and 
spleens were removed as described previously [79], and 
lobes/sections divided between bacteriology and histology 
analyses. For bacterial load analysis, each tissue was homog-
enized in 2 ml sterile PBS (1x). Each tissue homogenate 
volume was recorded and serially diluted in sterile PBS 
(1x) and 100 µl of each dilution was plated in duplicate 
onto Middlebrook 7H11 OADC selective agar. Plates were 
incubated at 37 °C for up to 4 weeks. Following incubation, 
colonies were enumerated (as c.f.u.), and the concentration 
of total bacilli in each sample homogenate was calculated. 
Bacterial load data were expressed as log10(total c.f.u.) 
and statistical significance was assessed with the one- way 
ANOVA test followed by Tukey HSD post- hoc test using 
the R package rstatix v0.6.0. For histological analysis, 
tissue representative of each lung and spleen, sampled 
consistently between animals, was processed routinely (by 
formaldehyde fixation) and embedded in paraffin wax. 
Sections (thickness of approximately 5 µm) were stained 
with haematoxylin and eosin. The nature and severity of the 
lesions were assessed by a 'blinded' veterinary pathologist, 
using a subjective scoring system as described elsewhere 
[81]. For the spleen, a score, based on number of lesions, 
was calculated. For the lung, each lobe was assigned a score 
as follows: 0, normal; 1, very few or small lesions, 0–10 % 
consolidation; 2, few or small lesions, 10–20 % consolida-
tion; 3, medium sized lesions, 20–33 % consolidation; 4, 
moderate sized lesions, 33–50 % consolidation; 5, 50–80 
% consolidation, extensive pneumonia, >80 % consolida-
tion, plus a number of foci of necrosis. Scores from each 
lobe were combined and a mean score from lung lobes and 
spleen was calculated for each group. Group mean histo-
pathology scores were then compared between groups and 
with bacterial loads and statistical significance was assessed 
with the Kruskal–Wallis test followed by Dunn post- hoc 
test with Benjamini–Hochberg correction using the R 
package rstatix v0.6.0. All vaccine groups, including saline 
negative controls, showed similar weight profiles during 
both the vaccination and challenge phases of the study, and 
no animals reached their humane endpoint prior to the end 
of the experiment.
RESULTS
Whole-genome sequencing of M. microti strains
Using PacBio and Illumina sequencing data, we gener-
ated the full- length genome sequences of five M. microti 
strains: OV254 (vole isolate) [42], ATCC 35782 (M.P. 
vaccine strain) [37], 94-2272 (clinical isolate) [17], Maus 
III (clinical isolate, also known as strain 6740/00 or B3) 
[30] and Maus IV (clinical isolate, also known as strain 
1479/99 or B4) [30, 82]. Overall, the genomes of the five 
M. microti strains were highly similar in terms of size and 
global organization (Table 1, Fig. S2), whereby the clinical 
M. microti isolates contained the largest genomes with, 
on average, an additional 14.1 and 17.5 kb as compared 
to strains OV254 and ATCC 35782, respectively (Table 1). 
Some of the most evident differences found corresponded 
to variations in the insertion sites and the copy number of 
IS6110 insertion elements (Fig. 1a, Table 1). Notably, M. 
microti strains depicted differences in their CRISPR- Cas 
loci that coincided with IS6110 insertion events (Fig. 1b). 
ATCC 35782 was the only M. microti strain studied here 
with a potentially intact CRISPR- Cas locus, albeit with 
shorter repeat/spacer clusters, as compared to the M. 
tuberculosis H37Rv control strain (Fig. 1b). By contrast, the 
other four M. microti strains displayed truncated CRISPR-
 Cas loci, with both cas1 and cas2 genes being missing 
and csm6 being either fully or partly deleted (Fig. 1b). A 
section of the repeat/spacer region was identical between 
all five M. microti strains, for which five out of six spacers 
matched spacers of M. tuberculosis H37Rv, in agreement 
with previous spoligotyping studies [17, 30, 83]. Further 
database comparisons showed that the remaining sixth 
spacer of this region was only detected in a few strains of 
TbD1- intact M. tuberculosis and Mycobacterium africanum 
strains, as well as in M. microti ATCC 19422 (also known as 
Table 1. Genomic characteristics of sequenced M. microti strains
Strain Genome length 
(bp)
No. of IS6110 
elements
No. of annotated 
genes
No. of core 
genes
No. of additional 
genes
No. of unique 
genes
No. of called 
variants
OV254 4 369 915 13 4114 3984 33 16 n/a
ATCC 35782 4 366 549 8 4103 3984 27 11 505
94-2272 4 384 561 15 4130 3994 45 10 484
Maus III 4 382 575 16 4116 3996 37 2 532
Maus IV 4 385 022 16 4137 3992 42 22 516
n/a, not applicable.
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strain ‘12’), which is consistent with a previous study that 
focused on the direct repeat (DR) locus of MTBC members 
[83]. Strain ATCC 35782 harboured additional spacers and 
repeats, as compared to the other M. microti strains, for 
which half of them were identical to the ones found in M. 
tuberculosis H37Rv (Fig. 1b), whereas others were mainly 
detected in TbD1- intact M. tuberculosis, M. africanum, 
M. bovis and BCG vaccine strains, in agreement with 
previous spoligotyping studies [17, 30, 83]. Interestingly, 
the CRISPR- Cas locus of M. microti ATCC 35782 appeared 
identical to the one described for M. microti ATCC 19422.
Gene synteny within M. microti strains and 
polymorphisms affecting ESX-5 type VII protein 
secretion
To further investigate genomic variability within M. microti 
strains, reconstructed genomes were annotated using bacte-
rial core databases and a customized mycobacterial database 
(see Methods). On average, 4120 genes were identified for 
each genome (Table 1), including, on average, 4039 (98.0 %) 
protein- encoding genes. Following gene annotation, we 
sought orthologous and non- orthologous genes among the 
five M. microti strains (Fig. S3a, b). Most of the protein- 
encoding genes (on average 3990, 98.8 %) belonged to a 
core gene set that was shared by all five M. microti strains 
(Table 1). However, additional orthologues (on average 37; 
0.9 %) were only identified in some strains but not in others, 
and a few genes (on average 12; 0.3 %) were unique to a 
specific M. microti strain (Tables 1 and S1). While most 
of these unique genes were annotated as encoding hypo-
thetical proteins or PPE/PE_PGRS family proteins, whose 
functions are still unknown, for some others a more specific 
role was suggested by the annotation (Fig. S3c, Table S1). As 
examples, the CRISPR- associated endonuclease genes cas1 
and cas2 were only found in strain ATCC 35782 (Fig. 1b), 
while the gene encoding the antitoxin VapB39 was unique 
to strain 94-2272 (Table S1). Moreover, we found important 
variations in the locus commonly referred to as RD5 that 
contains three phospholipase C genes (plcA- B- C) as well 
as the ppe38- ppe71- esxX- esxY locus (Fig. 2a), which is in 
agreement with a previous study that defined this locus as 
a hypervariable region within the MTBC members [84]. 
The three clinical strains 94-2272, Maus III and Maus IV 
harboured a full gene set at this locus that resembled that 
of most M. tuberculosis strains (Fig. 2a). By contrast, the 
vole strain OV254 showed the smallest locus and lacked 
plcA, plcB and part of plcC, as well as the ppe38, ppe71, 
esxX and esxY genes (Fig. 2a), a deletion that was previ-
ously characterized as RD5mic [30, 84]. As for strain ATCC 
35782, the full set of plcA- B- C genes was present, as was 
the single ppe71 gene, whereas ppe38, esxX and esxY were 
absent (Fig. 2a). Importantly, previous reports found that 
a functional copy of either ppe38, or its almost identical 
homologue ppe71, is needed for the export of the so- called 
PPE- MPTR and PE_PGRS proteins by the cognate ESX-5 
type VII secretion system [73, 84]. Deletion of the ppe38-71 
Fig. 1. IS6110 insertion element profiles and type III- A CRISPR- Cas locus in M. microti strains. (a) IS6110 elements (black bars) identified 
along the genome of each M. microti strain. The number of IS6110 elements is indicated at the top of each coloured bar. The genome size 
is in bp. (b) Type III- A CRISPR- Cas locus in M. microti strains as compared to M. tuberculosis H37Rv. Repeats are coloured in grey; spacers 
that are identical between M. tuberculosis H37Rv and M. microti strains are coloured in black, while those that are specific either to M. 
tuberculosis H37Rv or to M. microti strains are coloured in yellow and orange, respectively.
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locus made M. tuberculosis more virulent in animal models 
and this deletion occurred at the branching point of the 
hypervirulent modern Beijing strains [73]. RD5- like 
deletions, abrogating PE_PGRS/PPE- MPTR secretion, 
have occurred independently in multiple branches of the 
animal- adapted MTBC members [72, 84]. In contrast, these 
deletions are relatively rare in the closely related human- 
associated M. africanum strains of lineages L5 and L6, and 
have not been described in MTBC members infecting chim-
panzees, seals and sea lions [72, 74, 84]. However, we did 
previously report reduced levels of PE_PGRS secretion and 
PPE- MPTR immunogenicity in M. africanum L5 isolates 
that did have a functional ppe38/71 copy [72]. Based on 
these observations, we investigated protein secretion in 
the M. microti strains ATCC 35782, 94-2272, Maus III and 
OV254. In addition, we introduced the ppe38-71 locus of 
M. tuberculosis CDC1551 on an integrative plasmid to 
OV254 (OV254- C), which lacks an endogenous copy of 
either ppe38 or ppe71. As expected, ATCC 35782 secreted 
PE_PGRS proteins as well as other ESX-5 substrates, EsxN 
and PPE41, that are not dependent on ppe38/71 for secretion 
(Fig. 2b). Inversely, while OV254 did secrete regular levels 
of EsxN, this strain did not secrete any PE_PGRS proteins, 
as was expected due to its RD5mic deletion. This phenotype 
was fully complemented in OV254- C, confirming the 
ppe38-71 locus deletion as the cause of this secretion defect. 
Surprisingly, OV254 also did not secrete the ppe38/71- 
independent ESX-5 substrate PPE41 and this phenotype 
was not affected by complementation of the ppe38-71 locus. 
Detailed investigation of the genome sequence of OV254 
revealed that this strain has a 2- bp insertion in the coding 
sequence of ppe41 (Tables S2 and S3) explaining this pheno-
type. Finally, both human isolates 94-2272 and Maus III had 
clearly reduced to fully deficient PE_PGRS secretion and 
relatively low levels of PPE41 secretion, while the ESX-5 
substrate EsxN was unaffected (Fig. 2b).
Polymorphism signals among M. microti strains
Next, we compared the five M. microti strains at the base 
resolution by mapping sequencing reads from each strain 
against the reconstructed genome of the vole strain OV254, 
followed by calling variants (SNPs and indels). Between 484 
and 532 variants were detected for each M. microti strain as 
compared to OV254, accounting for a total of 990 unique 
variants (Tables 1 and S2). Among these variants, 231 were 
shared by the four M. microti strains (Fig. 3a), which corre-
sponded to polymorphism signals unique to OV254 as no 
variants were detected at these positions when mapping 
OV254 sequencing reads against its own genome. Among 
the four M. microti strains studied, ATCC 35782 depicted 
the highest number of specific variants (Fig. 3a). The 243 vari-
ants specifically detected for this strain affected various genes, 
notably: eight genes associated with the type VII secretion 
system, i.e. espK, esxE, eccD1 (adjacent to the deleted RD1mic 
region of difference), eccC3, mycP3, eccC5, eccD5 and mycP5; 
five genes involved in stress response (such as fbpB, mshA, 
proX and sodC); and six genes participating in resistance to 
Fig. 2. Phospholipase C locus and ESX-5 type VII protein secretion in M. microti strains. (a) Phospholipase C locus in M. microti strains. (b) 
Immunoblot secretion analysis of PE_PGRS proteins, PPE41 and EsxN, in M. microti strains. OV254- C corresponds to the OV254 strain 
complemented with the ppe38-71 locus from M. tuberculosis. SigA was used as a loading and lysis control. M, Molecular mass.
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antibiotics and toxic compounds (including blaC, ctpV and 
stp) (Fig. 3b, Table S2). Interestingly, the number of specific 
variants identified for the human isolates 94-2272, Maus III 
and Maus IV was much more reduced than for strains OV254 
and ATCC 35782 (80, 136 and 101, respectively), which was 
due to the detection of 127 variants that were common to 
the three clinical isolates (Fig. 3a). Among the genes affected 
by these common variants, two genes were associated with 
type VII secretion systems (eccB5 and espI), four genes were 
involved in stress response (including pncB2, mca and deaD), 
and one gene was related to processes involved in pathogen-
esis (rpfA) (Fig. 3c, Table S2).
Genomic variability between M. microti strains and 
M. tuberculosis
Next, we investigated the genomic variability between 
M. microti and M. tuberculosis by aligning sequencing reads 
from each M. microti strain against the reference genome 
of M. tuberculosis H37Rv. The four regions of difference 
Fig. 3. Polymorphism signals detected within M. microti strains. (a) Intersections of called variants (blue bars) within M. microti strains 
when compared to the genome of OV254. Black circles in the bottom matrix layout indicate the strains that are part of each intersection. 
The number of called variants within each intersection set is indicated at the top of each black bar. (b, c) Functional categories of genes 
affected by variants specific to strain ATCC 35782 (b), and by variants common to strains 94-2272, Maus III and Maus IV (c). The number 
and percentage of genes within each category are indicated.
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(RDs), from RD7 to RD10, characteristic for M. africanum 
L6 and animal- adapted lineages of tubercle bacilli [46, 85], 
were deleted in all M. microti strains as compared to M. 
tuberculosis H37Rv (Table 2,Fig. S4). In addition, one of both 
M. tuberculosis H37Rv prophage regions, phiRv1 (RD3), 
was missing in all M. microti strains, while the prophage 
region phiRv2 (RD11) was present (Table 2, Fig. S4) [30]. 
However, all M. microti strains lacked the IS6110 insertion 
element present in the RD11 region of M. tuberculosis H37Rv. 
M. microti strains were also characterized by missing the 
RD1mic region (Table 2, Fig. S4), which encompasses a large 
portion of genes encoding the ESX-1 secretion system, 
including ESAT-6 family proteins EsxA and EsxB. This 
genomic region is present in M. tuberculosis H37Rv and partly 
overlaps with the RD1BCG region absent from BCG strains 
[30, 49]. The MiD3 region was absent from all M. microti 
strains tested, while the presence or absence of regions MiD1 
and RD5mic, which correspond to type III- A CRISPR- Cas 
and phospholipase C loci, respectively, was variable among 
strains (Figs 1b, 2a and S4, Table 2). As for the MiD2 region, 
it was only absent from strain OV254, but present in all other 
M. microti strains (Table 2, Fig. S4). Moreover, both genes 
rv3019c and rv3020c, encoding the ESAT-6 like proteins EsxR 
and EsxS, respectively, were missing from all five M. microti 
strains, in agreement with previous findings [86]. In addition 
to these, between 2051 and 2128 variants (SNPs and indels) 
were detected for each M. microti strain relative to M. tubercu-
losis H37Rv. These variants were uniformly detected along the 
genome of M. tuberculosis H37Rv and corresponded to a total 
of 2962 unique variants (Fig. S5, Table S3). Among these vari-
ants, 519 were only detected in OV254 and/or ATCC 35782 
strains, but not in human isolates 94-2272, Maus III and Maus 
IV. These variants were notably enriched in genes associated 
with type VII secretion systems (eccA5, eccC2, eccC3, eccD1, 
eccD4, eccD5, esxE, esxL, esxN, mycP3, mycP4 and mycP5) and 
with type II toxin–antitoxin systems (vapC31 and vapC37), as 
well as in genes involved in DNA metabolism (such as cas1, 
end and uvrC), in pathogenesis (hbhA and rpfA), in resistance 
to antibiotics and toxic compounds (including blaC and 
ctpV), in RNA metabolism (such as rpoB and rpoC) and in 
stress responses (including cfp29, fbpB, mshA, proX and sodC) 
(Fig. 4a, Table S3).
Genome-based phylogeny
To assess the genome- based phylogeny of M. microti strains 
relative to M. tuberculosis, we included the publicly available 
whole- genome sequencing data of 11 additional M. microti 
strains of various origins: strain ATCC 19422, which was 
isolated from a vole by Dr Wells [3]; strains 416/01 and 
8753/00 with a llama- type spoligotype; and eight strains 
named G25821 to G25828 that were isolated from wild 
boars in Italy between 2003 and 2011 [9]. The results of 
these comparisons showed that between 2045 and 2323 vari-
ants (SNPs and indels) were detected for each of these 11 
additional M. microti strains as compared to M. tuberculosis 
H37Rv, extending the total number of unique variants to 
4019 (Table S3). A maximum- likelihood phylogenetic tree 
was inferred on all M. microti strains from 2993 variable sites 
covering 3004 unique SNPs and rooted using M. tuberculosis 
H37Rv (Fig. 4b). Phylogenetic reconstruction highlighted 
distinct groups of M. microti strains that were linked either 
by their origin (human and wild- boar isolates) and/or by 
their spoligotype (‘llama’ vs ‘vole’). Indeed, M. microti strains 
showing a vole spoligotype that successfully infected humans 
(94-2272, Maus III and Maus IV) clustered separately from 
strains harbouring a llama spoligotype (ATCC 19422 and 
35782, 416/01 and 8753/00) and from strains infecting wild 
boars (G25821 to G25828) (Fig. 4b).
Virulence evaluation of M. microti strains in SCID 
mice
For exploring the virulence of four selected M. microti strains 
(OV254, ATCC 35782, 94-2272 and Maus IV) relative to 
M. tuberculosis H37Rv and BCG Pasteur control strains, we 
used an infection assay of SCID mice, as this model provides 
Table 2. Regions of difference (RDs and MiDs) in M. microti strains
Region OV254 ATCC 35782 94-2272 Maus III Maus IV
RD1mic Absent Absent Absent Absent Absent
RD3 Absent Absent Absent Absent Absent
RD7 Absent Absent Absent Absent Absent
RD8 Absent Absent Absent Absent Absent
RD9 Absent Absent Absent Absent Absent
RD10 Absent Absent Absent Absent Absent
MiD3 Absent Absent Absent Absent Absent
RD11 Partial Partial Partial Partial Partial
MiD1 Absent Present Partial Partial Partial
RD5mic Absent Partial Present Present Present
MiD2 Absent Present Present Present Present
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Fig. 4. Polymorphism signals detected between M. microti strains and M. tuberculosis H37Rv. (a) Functional categories of genes affected 
by variants specific to strain OV254 and/or strain ATCC 35782 as compared to M. tuberculosis H37Rv. The number and percentage of 
genes within each category are indicated. (b) Maximum- likelihood phylogenetic tree of M. microti strains. Branch lengths are proportional 
to nucleotide substitutions detected relative to M. tuberculosis H37Rv, used as outgroup strain for phylogenetic reconstruction. Support 
values obtained from 1000 bootstrap replicates are indicated in brown as percentages. Scale bar represents the number of substitutions 
per site.
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a rapid and sensitive method for evaluating the in vivo growth 
characteristics of mycobacterial strains during the acute phase 
of infection [31, 87–90]. This approach showed that all four 
tested M. microti strains were less virulent than M. tubercu-
losis H37Rv, as mice infected with the latter strain reached 
the humane endpoint (weight loss of more than 20 %) about 
3–4 weeks post- infection (median time 28 days), when mice 
infected with M. microti or BCG strains were still well and 
gaining weight (Fig. 5). However, in the following weeks, 
a clear separation occurred between the two tested human 
clinical M. microti isolates Maus IV and 94-2272 on one 
hand, and the vole isolates OV254 and ATCC 35782 on the 
other hand. Indeed, mice infected with Maus IV reached the 
humane endpoint at about 8 weeks post- infection (median 
time 58 days; log- rank test vs H37Rv P <10−4), followed by 
strain 94-2272- infected mice at 11–12 weeks post- infection 
(median time 81 days; log- rank test vs H37Rv P <10−4), 
whereas mice infected with the BCG Pasteur control strain 
reached the humane endpoint starting from 14 weeks post- 
infection (median time 106 days; log- rank test vs Maus IV 
or 94-2272 P <10−4) (Fig. 5). By contrast, mice infected with 
strains OV254 or ATCC 35782 did not reach the humane 
endpoint during the experiment and were still in good health 
21 weeks post- infection when the experiment was stopped 
(log- rank test vs BCG Pasteur P <10−5) (Fig. 5). These results 
were similar to observations obtained by a preliminary, pilot 
experiment using a slightly different set of strains and fewer 
mice (Fig. S6). We conclude from the combined data that 
M. microti strains, including clinical isolates, showed lower 
virulence than the M. tuberculosis H37Rv control in the 
highly susceptible SCID mouse model, whereby the strongest 
attenuation was observed for the OV254 and ATCC 35782 
Fig. 5. Virulence evaluation of M. microti strains relative to the control strains BCG Pasteur and M. tuberculosis H37Rv in SCID mice. A 
total of 13 SCID mice per group were infected intravenously via the lateral tail vein with 1×106 c.f.u. in 200 µl of PBS (1x). (a) Bacterial 
load in the spleen of infected mice after 1 day of infection. N=3 mice per group. The results are shown as the mean±sd. (b) Percentage 
of weight change of infected SCID mice over time. N=10 mice per group. Coloured lines and surrounding areas represent the mean±sd. 
(c) Percentage of survival of infected SCID mice over time. N=10 mice per group. Mice were killed when reaching the humane endpoint, 
defined as a weight loss of more than 20 %, in accordance with ethics committee guidelines.
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vole isolates (Fig. 5). This finding is of particular importance 
as it confirms the safety of these strains even in immunodefi-
cient hosts and thereby encouraged us to conduct additional 
preclinical vaccination studies with one of these strains.
Protective efficacy of the highly attenuated 
M. microti ATCC 35782 strain in a preclinical 
vaccination model
From some older reports in the scientific literature, we know 
that the M. microti M.P. Prague strain (ATCC 35872; Fig. S1) 
was used successfully in the 1960s in former Czechoslovakia 
for large- scale human vaccination trials, where it showed a 
protective efficacy similar to that of BCG [37]. However, with 
the improvement of the TB situation in Europe and political 
changes since then, this vaccine strain has nowadays almost 
been forgotten. Given the strong attenuation and harmless-
ness of ATCC 35872 in SCID mice observed here, as well as 
the availability of the complete genome sequence that we have 
generated, it was of particular interest to evaluate the protec-
tive efficacy conferred by this strain in the established low- 
dose aerosol guinea pig model, a preclinical animal model 
that is often used for classifying the protective efficacy of TB 
vaccine candidates in head- to- head comparison studies in 
the framework of European TB vaccine consortia [79, 91]. In 
this experiment, which lasted for 16 weeks, we also included 
an ESX-1 complemented version of the strain ATCC 35782, 
named ATCC 35872::ESX-1, in addition to BCG Danish- 
vaccinated and unvaccinated (saline) control animals. As 
shown in Fig. 6(a), vaccination with strains ATCC 35782, 
ATCC 35782::ESX-1 and BCG Danish induced significant 
Fig. 6. Protective efficacy of the vaccine candidates in the guinea pig low- dose infection model. Eight guinea pigs per group were 
vaccinated once subcutaneously on the nape with 5×104 c.f.u. in 250 µl of PBS (1x) and challenged 12 weeks after immunization by 
the aerosol route with 10–20 c.f.u. M. tuberculosis/lungs. Bacterial load (a), histological analysis of consolidation (b), and representative 
photomicrograph images of group mean lesion pathology from sections (c) of lungs and spleen of guinea pigs vaccinated with M. microti 
strains ATCC 35782, ATCC 35782::ESX-1 or BCG Danish or unvaccinated (saline control) after 4 weeks of infection with M. tuberculosis. (a) 
N=8 guinea pigs per group; mean±sem. One- way ANOVA test followed by Tukey HSD post- hoc test: ns, not significant; ***, P <0.001. (b) 
N=8 guinea pigs per group; mean±sem. Kruskal–Wallis test followed by Dunn post- hoc test: ns, not significant; *, P <0.05; ***, P <0.001. (c) 
Haematoxylin and eosin stained tissue sections of formalin- fixed and paraffin- embedded lung (×15 objective) and spleen (×25 objective).
13
Orgeur et al., Microbial Genomics 2021;7:000505
protection against M. tuberculosis as compared to animals that 
had received saline controls (one- way ANOVA test: lungs, 
P=9.2×10−8; spleen, P=1.6×10−8). Accordingly, the mean 
histopathological scores, based on the number and severity of 
lesions, observed in lungs and spleens of vaccinated animals 
was reduced as compared to unvaccinated animals (Fig. 6b, c) 
(Kruskal–Wallis test: lungs, P=6.7×10−7; spleen, P=3.6×10−5). 
These results emphasize the potential of strain ATCC 35782 
to protect against an M. tuberculosis challenge in the sensi-
tive guinea pig model. As indicated by the c.f.u. counts 
obtained from lungs and spleens, the protective efficacy of 
M. microti ATCC 35782 against TB was equivalent to that of 
BCG (Fig. 6a; Tukey HSD post- hoc test P >0.05). Given the 
much stronger attenuation of ATCC 35782 in comparison 
to BCG in the SCID mouse virulence model, the significant 
protection conferred by strain ATCC 35782 relative to unvac-
cinated controls is still of particular interest for vaccination 
strategies in immunocompromised hosts, where BCG is 
contra- indicated [92].
DISCUSSION
In this work, we have described and analysed the complete 
genome sequences of five M. microti strains, from both 
human and vole origin, and have tested the protein secretion, 
virulence and vaccine potential of selected strains. While M. 
microti has traditionally been associated with voles, due to 
the work of Dr Wells and subsequent reports [3, 5, 93], the 
number of mammalian hosts from which M. microti strains 
have been isolated has continuously grown in recent years, 
thereby allowing certain M. microti strain subtypes to be 
detected that are specifically associated with particular hosts.
Within the MTBC, M. microti is the most closely related to 
Mycobacterium pinnipedii strains, with one main difference, 
which is the specific absence of the RD1mic genomic region 
from M. microti strains, and the presence of this region in 
M. pinnipedii [7, 30, 94]. Most interestingly, RD1mic overlaps 
in part with the region of difference 1 (RD1BCG) absent from 
BCG strains [33, 34, 95]. In the absence of inter- strain recom-
bination events, the deletion of a non- repetitive region of the 
chromosome cannot be repaired and, thus, will characterize 
all the descendants of the bacterial clone in which the dele-
tion occurred [7, 94]. Thus, the RD1mic deletion represents a 
reliable genotypic marker that links all strains showing this 
characteristic genomic mark to a recent common ancestor [7]. 
Hence, our first objective was to follow up the evolutionary 
events that happened since this bottleneck and determine by 
which degree M. microti isolates of human origin differed 
from the vole isolates, including those that were previously 
used as live attenuated vaccines against TB.
As outlined in Results and Fig. 1(a), the in silico- generated 
genome- wide IS6110 insertion map indicated the variable 
presence of 8 to 15 IS6110 elements in the tested strains, with 
several common positions shared between some strains. The 
three clinical M. microti isolates showed the greatest overlap 
of their IS6110 insertion profiles, pointing to a close genomic 
relationship, which was also observed in the gene content and 
gene arrangements inside the polymorphic CRISPR- Cas and 
phospholipase C- PPE38 region (Figs 1b and 2a). Indeed, the 
clinical isolates all lacked the genes encoding Cas1, Cas2 and 
part of Csm6 protein in the CRISPR- Cas locus, pointing to 
likely ancestral homologous recombination events involving 
IS6110 elements in a common progenitor strain. The pres-
ence of cas1, cas2 and csm6 genes in the ATCC 35782 vaccine 
strain suggests that this truncation of the CRISPR- Cas locus 
in clinical strains occurred in a subgroup of M. microti strains, 
and that the common progenitor strain in which the deletion 
of the RD1mic region had occurred still carried a full CRISPR-
 Cas gene set, similar to M. tuberculosis. Moreover, the pres-
ence of certain spacers in the DR region, used for generating 
spoligotyping profiles, did not necessarily correlate with the 
host species, as ATCC 35782, which is described as a vole 
isolate (OV166) [37], carries more spacers (corresponding 
to the so- called llama spoligotype profile) than the human 
isolates and the OV254 strain, which all show a vole spoligo-
type profile with only the second spacer cluster present. This 
finding is consistent with the variety of different spoligotypes 
observed for M. microti strains isolated from wild boars [9] 
and underlines that spoligotype information does not always 
represent a reliable marker for phylogenetic reconstruction.
Another such polymorphic region in MTBC genomes is the 
plcABC- ppe38 locus, which corresponds to the RD5 region 
(Fig. 2a). Like the above- mentioned CRISPR- Cas DR region, 
the phospholipase C- encoding genes plcA, plcB, plcC and plcD 
also represent a preferential target for IS6110 transposition 
[96] and, hence, are associated with frequent insertion- and 
deletion- causing recombination events, as can be seen for 
strain OV254. While in previous work we have speculated 
that the presence or absence of certain of these four plc genes 
might have an impact on the level of virulence of M. microti 
[30], a hypothesis which was based on a previous report on 
M. tuberculosis Mt103 mutants [97], more recent studies 
did not confirm an impact of plc genes on the virulence of 
M. tuberculosis H37Rv and Mt103 [98]. Our observation that 
M. microti ATCC 35782 and the three tested clinical M. microti 
strains all harbour an intact plcABC gene cluster (Fig. 2a), but 
differ strongly in virulence, further dismisses the hypothesis 
of a putative impact of plc genes in the virulence of MTBC 
members. However, plcABC are not the only variable genes 
in this RD5mic locus, as it also includes the ppe38, ppe71, esxX 
and esxY genes. Whereas all human isolates had this four- 
gene cluster intact, vole isolate ATCC 35782 has undergone 
a common recombination event between the almost identical 
ppe38 and ppe71 genes, known as an RvD7 deletion, that 
results in the effective deletion of ppe38, esxX and esxY [84]. 
Concurrent with previous work, we found that this single 
ppe38/71 copy was sufficient for functional PE_PGRS secre-
tion in ATCC 35782, but that the RD5mic deletion in OV254 
abrogated PE_PGRS secretion (Fig. 2b), similar to other RD5 
deletions in the MTBC [74]. Complementation of OV254 
with the four- gene ppe38-71 locus of CDC1551 resulted in 
high levels of PE_PGRS secretion. Interestingly, the human 
isolate Maus III showed little to no functional PE_PGRS 
secretion despite having a full ppe38-71 locus. This finding is 
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reminiscent of the strongly decreased PE_PGRS secretion and 
PPE- MPTR immunogenicity reported for lineage L5.2 strains 
of M. africanum [72], pointing to the existence of additional 
polymorphisms influencing PE_PGRS and PPE- MPTR secre-
tion in these strains to be identified by future research.
Overall, our findings suggest that the RD1mic- deleted common 
ancestor strain of the M. microti clade had the CRISPR- Cas 
and the plcABC- ppe38 loci intact, before strain- or group- 
specific deletions occurred. These results are also in good 
agreement with the phylogenetic reconstruction, which show 
that the three tested human isolates from various geographical 
origin clustered together in the phylogenetic tree (Fig. 4b). 
Importantly, the human isolates also showed higher virulence 
than the vole isolates in the SCID mouse model of infection, 
while being still much lower than that of the M. tuberculosis 
H37Rv control (Fig. 5). The overall lower virulence of M. 
microti strains, relative to the M. tuberculosis control can be 
explained by the absence of the ESX-1 secretion system in M. 
microti strains due to the deletion of the RD1mic region from 
all M. microti strains, in analogy to attenuated M. tuberculosis 
strains lacking the ESX-1 secretion systems [99]. The absence 
of ESX-1 functions was also judged as being one of the key 
attenuating factors of M. bovis BCG [31, 88]. Based on the 
results of the SCID mouse experiments, we can add that the 
absence of a functional ESX-1 system is also very likely one 
of the key factors of the attenuation of the previously used M. 
microti M.P. Prague vaccine strain (ATCC 35782). However, 
as suggested by the enhanced virulence of the three tested 
ESX-1- deficient clinical M. microti isolates, absence of ESX-1 
might not represent the only factor contributing to the strong 
attenuation of the ATCC 35782 and OV254 vole isolates.
These data are consistent with observations from investiga-
tions on the BCG vaccine strains, which apart from the 
loss of the RD1 region also carry additional attenuating 
mutations, like frameshift mutations in the pstB and phoT 
genes, encoding key components of the mycobacterial high- 
affinity phosphate- uptake system [49, 100]. Such mutations 
likely have accumulated during the 13 years of passaging of 
the original M. bovis strain on potato- ox- bile medium that 
Calmette and Guérin initially used [101], or during the more 
than 1000 passages in different research institutions, which 
today characterize the various BCG sub- strains [49, 102]. 
Interestingly, for the M. microti M.P. Prague vaccine, similar 
events appear to have happened. As outlined in their report 
from 1976, Sula and Radovsky described the M. microti 
strain that they initially received from Dr Wells (OV166) 
as too virulent for their vaccination purposes and, thus, 
had subjected the strain to additional in vitro passaging, 
after which the strain was considered as safe for use as a 
human vaccine [37, 38]. It is likely that during these in vitro 
passages additional attenuating mutations were introduced 
into the strain, which also seem to contribute to the strong 
attenuation of ATCC 35782 in SCID mice, where it was 
more attenuated than BCG (Fig. 5).
As another perspective, the observed higher virulence of 
the human M. microti isolates relative to the vole M. microti 
strains confirms that under certain conditions ESX-1- 
deprived strains may still act as pathogens in susceptible 
hosts. These observations are consistent with the fact that 
several members of the MTBC are natural ESX-1 dele-
tion mutants and still occupy an important role as natural 
animal pathogens [1]. Besides M. microti, this is the case 
for 'Mycobacterium mungi' [103], the dassie bacillus [104] 
and 'Mycobacterium suricattae' [105], which appear to be 
closely related to the human M. africanum L6 clade of the 
MTBC [46]. Whether this situation is linked to specific 
host factors that increase the susceptibility of certain hosts 
or individuals to infection with ESX-1- deprived MTBC 
strains still remains to be addressed. From studies on 
human patients who became victims of generalized BCG 
infections (BCGitis), some key host factors essential for 
efficient control of mycobacterial infections, such as IFN-γ 
and IL-12 receptors, have been identified [106]; however, it 
is not known if any of these factors play a role in the natural 
infection cycle of voles with M. microti, or mongoose or 
meerkats with 'M. mungi' and 'M. suricattae', respectively. 
Alternatively, the natural infection routes with ESX-1- 
deprived strains in wildlife may differ strongly from the 
aerosolic spread of M. tuberculosis in humans [107].
Finally, we also tested the ATCC 35782 vaccine strain in a 
standard guinea pig vaccination model and found that this 
strain induced a protection level in the vaccinated guinea 
pigs that was significantly better than that observed for 
unvaccinated control animals, while being equivalent to 
the one induced by BCG Danish (Fig. 6). Taken together, we 
conclude that this strain, which has been used previously 
for the vaccination of more than half a million infants in 
former Czechoslovakia in the 1960s, still retains a substan-
tial vaccine potential that might be worth reconsideration 
under some specific situations. Given the very high level 
of attenuation observed for this live vaccine strain in the 
hypersusceptible SCID mouse model, the M. microti ATCC 
35782 strain might be an ideal candidate for vaccination of 
immunodeficient individuals, such as HIV- positive chil-
dren and adults for whom BCG vaccination is not recom-
mended [108, 109], but who might benefit the most from 
an immunization against TB.
In conclusion, we show here that M. microti harbours a 
substantial amount of diversity within its clade in addition 
to the common deletion of the RD1mic region. The combined 
findings of our study and those of previous analyses [46] 
suggest that the diversification since this RD1mic- associated 
evolutionary bottleneck has created several sub- clades of 
strains infecting different mammalian species, where they 
may maintain natural infection cycles. Given previous find-
ings that M. microti may infect a wider range of mammalian 
hosts than originally thought [7, 21], additional genome 
analysis from a larger number of animal isolates will 
further fine- characterize the phylogenomic structure of the 
M. microti clade. From analysis of the current litera-
ture, it also seems clear that human cases caused by M. 
microti remain an exceptional phenomenon. Thus, it is of 
importance to emphasize that the three strains isolated 
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from human patients included in our study cluster in a 
separate group of the phylogenetic tree, suggesting that 
both mycobacterial- strain- related factors and host- related 
factors might contribute to turn ESX-1- deleted M. microti 
strains into human pathogens. Whether in these special 
and rare cases humans might serve as a spillover host, 
similar to situations where other animal- adapted MTBC 
members, such as M. pinnipedii or M. bovis, may cause 
sporadic zoonotic human disease [1, 110–112], remains 
an open question, which is difficult to answer given the 
small number of available clinical isolates of M. microti. 
The full genome sequences of these strains provided here, 
thus, opens new perspectives for comparative analyses with 
larger datasets, as soon as they become available. Until 
then, we should consider M. microti strains as a clade of 
ESX-1- deficient MTBC strains with a substantial vari-
ability of virulence that ranges from completely attenuated 
members, such as the ATCC 35782 vaccine strain, to quite 
highly virulent strains, such as the Maus IV clinical isolate.
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